Platelet count response to H. pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection: a systematic review

Eradication of H. pylori improves thrombocytopenia in some patients with immune thrombocytopenic purpura by mechanisms that remain obscure. To determine the independent effect of H. pylori eradication therapy on platelet count response, the authors performed a systematic review of all studies reporting treatment responses compared to H. pylori-negative controls. The findings strengthen the causal association between H. pylori infection and immune thrombocytopenia in some patients. See related perspective article on page 759. Eradication of H. pylori improves thrombocytopenia in some patients with immune thrombocytopenic purpura by mechanisms that remain obscure. Platelet count responses may occur independently of H. pylori infection as a result of the immune modulating effects of macrolide antimicrobials or the removal of other commensal bacteria. We performed a systematic review of the literature to determine the effect of H. pylori eradication therapy in patients with immune thrombocytopenic purpura by comparing the platelet response in patients who were, and who were not infected with H. pylori. MEDLINE, EMBASE, Cochrane central registry and abstracts from the American Society of Hematology (from 2003) were searched in duplicate and independently without language or age restrictions. Eleven studies, 8 from Japan, were included enrolling 282 patients with immune thrombocytopenic purpura who received eradication therapy; 205 were H. pylori-positive and 77 were H. pylori-negative. The odds of achieving a platelet count response following eradication therapy were 14.5 higher (95% confidence interval 4.2 to 83.0) in patients with H. pylori infection (51.2% vs. 8.8%). No study reported bleeding or quality of life. Adverse events were reported in 12 patients. H. pylori eradication therapy was of little benefit for H. pylori-negative patients. These findings strengthen the causal association between H. pylori infection and immune thrombocytopenia in some patients. Randomized trials are needed to determine the applicability of H. pylori eradication therapy across diverse geographical regions.

[1]  J. Segal,et al.  Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. , 2009, Blood.

[2]  P. M. O'Connor,et al.  Long term platelet responses to Helicobacter pylori eradication in Canadian patients with immune thrombocytopenic purpura , 2008, International journal of hematology.

[3]  Y. Ikeda,et al.  Helicobacter pylori eradication shifts monocyte Fcgamma receptor balance toward inhibitory FcgammaRIIB in immune thrombocytopenic purpura patients. , 2008, The Journal of clinical investigation.

[4]  M. Luppi,et al.  Helicobacter pylori infection and chronic immune thrombocytopenic purpura: long-term results of bacterium eradication and association with bacterium virulence profiles. , 2007, Blood.

[5]  R. Stasi,et al.  Secondary immune thrombocytopenic purpura , 2007, Current opinion in hematology.

[6]  G. Pizzolo,et al.  Effect of Helicobacter pylori eradication on platelet count in idiopathic thrombocytopenic purpura: a systematic review and meta-analysis. , 2007, The Journal of antimicrobial chemotherapy.

[7]  I. Pabinger,et al.  Late spontaneous remissions in severe adult autoimmune thrombocytopenia , 2007, Annals of Hematology.

[8]  T. Sugiura,et al.  Helicobacter pylori-associated chronic idiopathic thrombocytopenic purpura and low molecular weight H. pylori proteins , 2007, Scandinavian journal of infectious diseases.

[9]  Chao‐Ping Yang,et al.  The role of Helicobacter pylori infection in children with acute immune thrombocytopenic purpura , 2006, Pediatric blood & cancer.

[10]  Y. Fukunaga,et al.  Implications for Induction of Autoimmunity via Activation of B-1 Cells by Helicobacter pylori Urease , 2006, Infection and Immunity.

[11]  T. Hibi,et al.  Effects of a Helicobacter pylori eradication regimen on anti-platelet autoantibody response in infected and uninfected patients with idiopathic thrombocytopenic purpura. , 2006, Haematologica.

[12]  Y. Shiratori,et al.  Eradication of Helicobacter pylori increases platelet count in patients with idiopathic thrombocytopenic purpura in Japan , 2005, European journal of clinical investigation.

[13]  G. Pineo,et al.  Helicobacter pylori eradication: Novel therapy for immune thrombocytopenic purpura? A review of the literature , 2005, American journal of hematology.

[14]  K. Ishizawa,et al.  Can the Helicobacter pylori eradication regimen induce platelet recovery in H. pylori‐negative patients with idiopathic thrombocytopenic purpura? , 2005, American journal of hematology.

[15]  K. Sakakibara,et al.  [Evaluation of the efficacy of an Helicobacter pylori eradication treatment for idiopathic thrombocytopenic purpura patients]. , 2004, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology.

[16]  E. El-Omar,et al.  Characteristics of Helicobacter pylori‐Induced Gastritis and the Effect of H. pylori Eradication in Patients with Chronic Idiopathic Thrombocytopenic Purpura , 2004, Helicobacter.

[17]  R. Genta,et al.  Helicobacter pylori and idiopathic thrombocytopenic purpura. , 2004, Annals of internal medicine.

[18]  J. Bussel,et al.  Does Helicobater pylori initiate or perpetuate immune thrombocytopenic purpura? , 2004, Blood.

[19]  Y. Oka,et al.  Molecular mimicry by Helicobacter pylori CagA protein may be involved in the pathogenesis of H. pylori‐associated chronic idiopathic thrombocytopenic purpura , 2004, British journal of haematology.

[20]  K. Slim,et al.  Methodological index for non‐randomized studies (MINORS): development and validation of a new instrument , 2003, ANZ journal of surgery.

[21]  C. O'Morain,et al.  Helicobacter pylori Infection , 1994 .

[22]  M. Hino,et al.  Platelet recovery after eradication of Helicobacter pylori in patients with idiopathic thrombocytopenic purpura , 2002, Annals of Hematology.

[23]  Madhuri S. Mulekar,et al.  Statistical Inference in Science , 2001, Technometrics.

[24]  I. Olkin,et al.  Meta-analysis of observational studies in epidemiology - A proposal for reporting , 2000 .

[25]  F. D’Acquisto,et al.  Anti-inflammatory activity of macrolide antibiotics. , 2000, The Journal of pharmacology and experimental therapeutics.

[26]  F. Mégraud,et al.  Geographic distribution of vacA allelic types of Helicobacter pylori. , 1999, Gastroenterology.

[27]  A. Gasbarrini,et al.  Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori , 1998, The Lancet.

[28]  E. Kuipers,et al.  Country‐specific constancy by age in cagA+ proportion of Helicobacter pylori infections , 1997, International journal of cancer.

[29]  J. George,et al.  Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. , 1996, Blood.

[30]  G. Papa,et al.  Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. , 1995, The American journal of medicine.

[31]  D. Forman,et al.  An international association between Helicobacter pylori infection and gastric cancer , 1993 .

[32]  T. A. S. Group.  An international association between Helicobacter pylori infection and gastric cancer , 1993, The Lancet.

[33]  Theeurogaststudygroup.  An international association between Helicobacter pylori infection and gastric cancer. The EUROGAST Study Group. , 1993, Lancet.

[34]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.